top of page

Insights and News Curated for Life Science Experts by Life Science Experts....
INSIGHTS HUB


Warren Buffett’s Hiring Rule: Why Integrity Comes First
Warren Buffett’s hiring philosophy has long been quoted in business circles, and for good reason. As he prepares to step down as CEO of...


Deepfakes: A Growing Threat to Hiring in the Life Sciences Industry
As Life Sciences recruiting becomes more selective and AI has continued advancement, incorporating these technologies into recruitment...


The FTC Ban on Non-Competes – From Life Science Recruiters’ Perspective
In a landmark decision, the Federal Trade Commission (FTC) has voted 3-2 to approve the issuance of a final rule that could reshape the...
Search
Beeline Medicines Launches with $300M Series A to Build Precision Autoimmune Pipeline
Stamford, CT and Boston, MA, April 15, 2026 (Globe Newswire) -- Beeline Medicines officially launched with $300 million in Series A financing led by Bain Capital, debuting with a portfolio of five clinical and preclinical programs in-licensed from Bristol Myers Squibb. The company's lead asset, afimetoran, is a once-daily oral TLR7/8 inhibitor for systemic lupus erythematosus currently in Phase 2, with data expected in the second half of 2026 ahead of a planned pivotal prog
Modulari-T Biosciences Appoints Tanya E. Borsuk as CEO to Lead Next Phase of Growth
Montreal and Highland Park, NJ, April 21, 2026 (Yahoo Finance) -- Modulari-T Biosciences has named Tanya E. Borsuk as its new chief executive officer. The leadership appointment is aimed at advancing the company’s strategic direction and accelerating development of its therapeutic platforms. The move positions the company to expand its pipeline and operational capabilities in the next stage of growth. Read full article here.
Medtronic Leads $100M Strategic Financing Round in Pulnovo Medical
New York, NY, April 19, 2026 (PRNewswire) -- Pulnovo Medical closed an oversubscribed $100 million strategic financing round led by Medtronic, alongside existing investors EQT, Qiming Venture Partners, OrbiMed, Gaorong Ventures, and Lilly Asia Ventures, and new investor HSG (formerly Sequoia China). Separately, Medtronic and Pulnovo entered into a commercial agreement contemplating potential future commercialization opportunities. Read full article here.
Paratus Names Alicia Secor as CEO and Expands Leadership Team for Growth
Boston, MA, and Singapore, April 22, 2026 (Paratus) -- Paratus Sciences has appointed Alicia Secor as president and chief executive officer. The company also expanded its leadership team to strengthen operational and strategic capabilities. These changes are intended to support Paratus’ next phase of growth and advancement of its scientific programs. Read full article here.
Eli Lilly to Acquire Kelonia Therapeutics in Deal Worth Up to $7B to Boost Cancer Pipeline
San Diego, CA, April 19, 2026 (Reuters) -- Eli Lilly has agreed to acquire Kelonia Therapeutics in a transaction valued at up to $7 billion. The deal includes an upfront payment along with additional milestone-based considerations tied to development progress. The acquisition is intended to strengthen Lilly’s oncology portfolio with next-generation cancer therapies. Read full article here.
Embecta to Acquire Owen Mumford in $300M Deal to Expand Drug-Delivery Portfolio
Parsippany, NJ, March 24, 2026 (Yahoo Finance) -- Embecta has agreed to acquire Owen Mumford to strengthen its drug-delivery business. The transaction, valued at approximately $300 million, will add a range of injection and medical device products to Embecta’s portfolio. The deal is expected to enhance the company’s capabilities in supporting patients with chronic conditions. Read full article here .
ImpediMed Appoints Erik Anderson as CEO
Brisbane, CA, April 7, 2026 (ImpediMed) — ImpediMed has named Erik Anderson as its new chief executive officer. The leadership change is intended to guide the company’s strategic direction and support expansion of its medical technology portfolio. The appointment comes as ImpediMed focuses on advancing its commercial operations and growth initiatives. Read full article here .
Neurocrine Biosciences Details $2.9B Deal to Strengthen Pipeline
San Diego, CA, April 7, 2026 (Yahoo Finance) -- Neurocrine Biosciences has outlined a transaction valued at approximately $2.9 billion aimed at expanding its therapeutic portfolio. The deal is designed to enhance the company’s pipeline with additional clinical-stage assets. The move supports Neurocrine’s strategy to drive long-term growth through targeted business development initiatives. Read full article here .
Hologic names Baxter's Previous Chair Jose Almieda as CEO
Marlborough, MA and New York, NY, April 7, 2026 (Business Wire) -- Hologic announced the close of its go-private acquisition by Blackstone and TPG at up to $79/share and simultaneously named José (Joe) Almeida as CEO, effective immediately. Almeida was previously Chairman/President/CEO of Baxter International (2016–2025) and before that CEO of Covidien through its Medtronic acquisition. He succeeds Steve MacMillan, who retired after 12+ years. Read full article here .
Gilead to Acquire Tubulis in $3.15B Deal with Up to $1.85B in Milestones
Foster City, CA and Munich, Germany, April 7, 2026 (Business Wire) -- Gilead Sciences has announced plans to acquire Tubulis to enhance its cancer treatment portfolio. The deal includes $3.15 billion in upfront cash, along with potential milestone payments that could bring the total value significantly higher. The acquisition adds advanced antibody-drug conjugate (ADC) candidates and platform technologies aimed at strengthening Gilead’s next-generation oncology pipeline. Re
GE HealthCare Completes $2.3B Intelerad Acquisition to Expand Imaging Capabilities
Chicago, IL, March 18, 2026 (Business Wire) -- GE HealthCare has finalized its $2.3 billion acquisition of Intelerad, a provider of medical imaging software solutions. The addition strengthens its presence in cloud-based imaging and extends capabilities into ambulatory and teleradiology markets. The company expects the business to generate substantial recurring revenue in its first full year under ownership. Read full article here .
Damora Therapeutics Names Jennifer Jarrett as President and CEO
Boston, MA, March 23, 2026 (Globe Newswire) -- Damora Therapeutics has appointed Jennifer Jarrett as president and chief executive officer, effective at the end of March. She brings extensive experience from prior leadership roles in biotech and investment banking. The company aims to leverage her expertise to advance its biologics pipeline for blood disorders. Read full article here .
bottom of page

